Skip to main content

Aims and scope

EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging.

Regular features include original research articles, short communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor.

Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome.

The journal also considers preliminary Research Articles or short communications that include novel findings, methods or radiopharmaceuticals with a high potential but limited data available, worth a preliminary information.

Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.

Topics include but not limited to innovative research covering all aspects of molecular imaging, e.g. radiopharmaceutical approaches with a high potential of clinical impact, important aspects in image reconstruction and accuracy, or within the theranostic field with therapy combinations or incorporation of artificial intelligence in image generation or interpretation.

 

Announcement
Since January 2024: New Editor-in-Chief - Dr. Irene Burger, Chief Medical Officer, Kantonsspital Baden AG

Articles

Annual Journal Metrics

  • 2022 Citation Impact
    3.2 - 2-year Impact Factor
    3.3 - 5-year Impact Factor
    0.932 - SNIP (Source Normalized Impact per Paper)
    0.853 - SJR (SCImago Journal Rank)

    2022 Speed
    14 days submission to first editorial decision for all manuscripts (Median)
    102 days submission to accept (Median)

    2022 Usage 
    492,385 downloads
    314 Altmetric mentions 

Need help with APC funding?

New Content Item

We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. ​​​​​​​Learn more here.

Check if your institution is a member

More than 500 institutions have partnered with BMC through the membership program. As an affiliated Author from a member institution, you may be entitled to submit your manuscript without paying the article processing charge (APC) or with a discount. Check here if your institution is a member!

New Content Item

Large prospective randomized trials are needed, to advance the application of new radiopharmaceuticals into clinical guidelines and daily routine. To generate the hypothesis and find novel approaches that can be tested in such highly complex and regulated trials, smaller scale “proof of mechanism” or phase 0 studies, preclinical research with a strong clinical focus, as well as analysis on retrospective data are needed. This will be the focus and strength of EJNMMI Research, at the intercept between clinical nuclear medicine, radiochemistry, biology, physics, drug development and radiation oncology.

This journal has been launched by Springer and is a companion journal to the EJNMMI family. Authors of papers with a focus on nuclear medicine, whose manuscript despite high quality is not accepted in the mother journal can submit to this daughter journal. Besides regular papers the journal gives the possibility to publish reviews, educational papers guidelines and short communications.

By this combination of different articles, I hope to establish a unique platform for nuclear medicine, with the potential to reach the important audience in clinic as well as in basic science.

Irene A. Burger, Editor-in-Chief



The EJNMMI Journal Family and EANM Springer Award

New Content Item

EJNMMI is part of the EJNMMI Journal Family. Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There you find details about the annual EANM Springer Prize.